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It is now well established that both CD4+ and CD8+
tumour-specific T-lymphocytes play critical roles in anti-
tumour immunity; thus there is a desirability to identify
both MHC class I and II-restricted tumour antigens that
induce immunogenic responses in both in-vitro models
and more significantly in an in-vivo environment. Many
current tumour antigens that are potential targets fall into
the category of cancer-germline (CG) antigens, and are
considered to represent good candidate antigens for
tumour immunotherapy based on their lack of expression
on normal somatic tissues. HAGE is a novel CG gene
expressed in a wide range of solid tumour tissue (eg.
around 20% of melanomas, one-third of lung cancers)
but also in haematological malignancies (in >50% and
>20% of chronic and acute myeloid leukaemias, respec-
tively). Here we describe the use of a combination of com-
puter algorithms to identify potentially immunogenic
peptides from the HAGE protein based on both predicted
HLA affinity and proteosomal cleavage sites. An HLA-A2-
binding motif contained within a longer HLA-DR-binding
sequence was identified. Two peptides representing either
the class I motif alone, or a longer peptide containing the
class I motif within the class II motif, were then screened
in in-vitro T cell sensitisation experiments using PBMC or
monocyte-derived dendritic cells from healthy donors or
CML patients; the class I peptide was also used in-vivo to
vaccinate HLA-A2-transfected mice. We demonstrate that
both these peptides are immunogenic in-vitro not only for
T cells from healthy donors, but also from CML patients,
as assessed by functional assays such as cytokine secretion
and cytotoxicity. Moreover, immunogenicity was con-
firmed by using MHC/peptide tetramers to show specific
expansion of sensitised T-cells. Furthermore, the class I
peptide also demonstrates immuno-genicity in-vivo fol-
lowing vaccination of HLA-A2-transfected mice. Spleen
cells isolated from these mice showed specific cytotoxicity
ex-vivo. We conclude that the HLA-DR-binding peptide
and the HLA-A2 motif contained therein may represent
potential vaccines for the immunotherapeutic treatment
of cancer, particularly CML, targeting the HAGE expres-
sion of a high proportion of tumours.
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